The Landmark malaria vaccine showed 77% efficacy in phase two trials. This R2 vaccine may be effective in preventing malaria, one of the diseases in the world that has claimed the lives of many. The female mosquitoes transmit malaria and yellow fever to the body. In 2019, about 400,000 malaria-related deaths were recorded.
This new vaccine went through clinical trials in Burkina Faso. According to reports, the Landmark malaria vaccine triggers the immune system in the body to fight the parasite. GlaxoSmithKline, the pharmaceutical company tried to utilize vaccination to fight the malaria pandemic in the ‘80s.
Researchers found out that proteins covered sporozoites that trigger a strong immune system response; however, their life cycle is very quick for natural immunity to identify and terminate the sporozoites, according to National Geographic.
Researchers wanted to develop a carrier that would have a punching bag that contains sporozoite protein so the immune system can fight the real thing before it gets to the liver.
This vaccine was commercially marketed as Mosquirix, but its potency reduced after twelve months.
Epidemiologist, Halidou Tinto, who is an expert in Malaria helped to carry out a trial of 450 children for the R21 vaccine. The new R21 vaccines make use of the same method Mosquirix uses, however, before the sporozoite protein had coated one in five proteins, the R21 vaccine coated five in five proteins.
The R21 vaccine made a 77% reduction in clinical malaria incidence, which is 2% greater than the 75% targeted by WHO in 2013 as an attempt to make the malaria problem mainstream pharmacology.
We are enthusiastic, but we still need phase three trials to confirm the efficacy and the safety of the vaccine before we move on.Tinto